Metastatic small cell lung cancer - an aggressive disease: a case report and literature review

Walid Shalata; Ismaell Massalha; Keren Rouvinov; Elron Oscar; Margarita Toker; Ashraf A-J; Yulia Dudnik; Alexander Yakobson

doi:10.1097/CAD.0000000000001119

Metastatic small cell lung cancer - an aggressive disease: a case report and literature review

Walid Shalata, Ismaell Massalha, Keren Rouvinov, Elron Oscar, Margarita Toker, Ashraf A-J, Yulia Dudnik, Alexander Yakobson

Research output: Contribution to journal › Article › peer-review

Abstract

In the present case study, we describe a 53-year-old male with an aggressive small cell lung cancer (SCLC) that was diagnosed in January 2019. Our patient was treated as first line of systemic chemotherapy consisting of cisplatin and etoposide followed by mediastinal prophylactic radiotherapy with good response later he received for his metastatic disease (M-SCLC) a rechallenge of systemic chemotherapy consisting of carboplatin, etoposide and dulvalumab with stable disease and after progression his disease he was treated with lurbinectedin and after four cycles he reached a complete radiologic response. To the best of our knowledge, this is the first case to be reported of M-SCLC patient treated with prior of two types of platinum combination with immunotherapy and reaching a complete radiologic response.

Original language	English
Pages (from-to)	1138-1141
Number of pages	4
Journal	Anti-Cancer Drugs
Volume	32
Issue number	10
DOIs	https://doi.org/10.1097/CAD.0000000000001119
State	Published - 1 Nov 2021

Keywords

complete response
lung disease
lurbinectedin
metastatic disease
small cell lung cancer

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/CAD.0000000000001119

Cite this

@article{fdc26f5ac7be49618277e817801f668c,

title = "Metastatic small cell lung cancer - an aggressive disease: a case report and literature review",

abstract = "In the present case study, we describe a 53-year-old male with an aggressive small cell lung cancer (SCLC) that was diagnosed in January 2019. Our patient was treated as first line of systemic chemotherapy consisting of cisplatin and etoposide followed by mediastinal prophylactic radiotherapy with good response later he received for his metastatic disease (M-SCLC) a rechallenge of systemic chemotherapy consisting of carboplatin, etoposide and dulvalumab with stable disease and after progression his disease he was treated with lurbinectedin and after four cycles he reached a complete radiologic response. To the best of our knowledge, this is the first case to be reported of M-SCLC patient treated with prior of two types of platinum combination with immunotherapy and reaching a complete radiologic response.",

keywords = "complete response, lung disease, lurbinectedin, metastatic disease, small cell lung cancer",

author = "Walid Shalata and Ismaell Massalha and Keren Rouvinov and Elron Oscar and Margarita Toker and Ashraf A-J and Yulia Dudnik and Alexander Yakobson",

year = "2021",

month = nov,

day = "1",

doi = "10.1097/CAD.0000000000001119",

language = "English",

volume = "32",

pages = "1138--1141",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Metastatic small cell lung cancer - an aggressive disease

T2 - a case report and literature review

AU - Shalata, Walid

AU - Massalha, Ismaell

AU - Rouvinov, Keren

AU - Oscar, Elron

AU - Toker, Margarita

AU - A-J, Ashraf

AU - Dudnik, Yulia

AU - Yakobson, Alexander

PY - 2021/11/1

Y1 - 2021/11/1

N2 - In the present case study, we describe a 53-year-old male with an aggressive small cell lung cancer (SCLC) that was diagnosed in January 2019. Our patient was treated as first line of systemic chemotherapy consisting of cisplatin and etoposide followed by mediastinal prophylactic radiotherapy with good response later he received for his metastatic disease (M-SCLC) a rechallenge of systemic chemotherapy consisting of carboplatin, etoposide and dulvalumab with stable disease and after progression his disease he was treated with lurbinectedin and after four cycles he reached a complete radiologic response. To the best of our knowledge, this is the first case to be reported of M-SCLC patient treated with prior of two types of platinum combination with immunotherapy and reaching a complete radiologic response.

AB - In the present case study, we describe a 53-year-old male with an aggressive small cell lung cancer (SCLC) that was diagnosed in January 2019. Our patient was treated as first line of systemic chemotherapy consisting of cisplatin and etoposide followed by mediastinal prophylactic radiotherapy with good response later he received for his metastatic disease (M-SCLC) a rechallenge of systemic chemotherapy consisting of carboplatin, etoposide and dulvalumab with stable disease and after progression his disease he was treated with lurbinectedin and after four cycles he reached a complete radiologic response. To the best of our knowledge, this is the first case to be reported of M-SCLC patient treated with prior of two types of platinum combination with immunotherapy and reaching a complete radiologic response.

KW - complete response

KW - lung disease

KW - lurbinectedin

KW - metastatic disease

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85119303757&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000001119

DO - 10.1097/CAD.0000000000001119

M3 - Article

C2 - 34232947

AN - SCOPUS:85119303757

SN - 0959-4973

VL - 32

SP - 1138

EP - 1141

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 10

ER -

Metastatic small cell lung cancer - an aggressive disease: a case report and literature review

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this